Status:
WITHDRAWN
Prognositc Factors in COVID-19 Patients Complicated With Hypertension
Lead Sponsor:
Chongqing Medical University
Conditions:
2019-nCoV
Eligibility:
All Genders
18-100 years
Brief Summary
There are currently no clinical studies reporting clinical characteristics difference between the hypertension patients with and without ACEI treatment when suffered with novel coronavirus infection i...
Detailed Description
At present, the outbreak of the new coronavirus (2019-nCoV) infection in Wuhan and Hubei provinces has attracted great attention from the medical community across the country. Both 2019-nCoV and SARS ...
Eligibility Criteria
Inclusion
- Adult aged \>=18years old;
- Diagnosed with 2019-nCoV. Diagnostic criteria including: Laboratory (RT-PCR) confirmed 2019-nCoV infection; CT of the lung conformed to the manifestation of viral pneumonia.
- Diagnosed with primary hypertension.
- Criteria for severe or critical ill conditions: Respiratory rate \>=30/min; or Rest SPO2\<=93%; or PaO2/FiO2\<=300mmHg.
Exclusion
- Near-death state (expected survival time less than 24 hours);
- Malignant tumor;
- Pregnancy or puerperium women;
- ACEI contraindication
- Patients who refused to participant.
Key Trial Info
Start Date :
January 25 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04272710
Start Date
January 25 2020
End Date
April 30 2020
Last Update
March 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China